

8th February, 2017

BSE Limited

1st Floor, New Trading Wing,
Rotunda Bldg, P.J. Towers,
Dalal Street, Fort,
Mumbai- 400 001

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra-Kurla Complex,
Mumbai – 400 051

Dear Sir / Madam,

Ref: BSE Scrip Code: 532979
NSE Symbol: PIRPHYTO

Sub: Outcome of Board Meeting held today:

1. Appointment of Mr. Rajiv Salvi as the Manager of the Company;
2. Financial Results for the quarter and nine months ended 31st December, 2016

Kindly refer to our letter dated 1st February, 2017 on the subject.

1. Appointment of Mr. Rajiv Salvi as the Manager of the Company:

Mr. Rajiv Salvi was appointed as the Manager of the Company for a period of 3 years with effect from 8th February, 2017. A brief profile of Mr. Salvi is enclosed as annexure A;

2. Financial Results:

Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2016 were approved. The Financial Highlights as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed. The said results have been subjected to Limited Review by the Auditors of the Company and a copy of their Limited Review Report is enclosed.


The meeting commenced at 11.00 a.m. and concluded at 12.15 p.m.

Request you to please take the above on record and oblige.

Thanking you,

Yours truly,

For Piramal Phytocare Limited


Rajesh Laddha
Director

Encl. a/a

Piramal Phytocare Limited
(Formerly known as Piramal Life Sciences Limited) | CIN : L73100MH2001PLC132523
Registered Office: Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013, India
Secretarial Dept. : Tower Annexe 1st Floor Ganpatrao Kadam Marg Lower Parel Mumbai 400 013.
T +91 22 3046 7953 F +91 22 3046 7855
W www.piramalphytocare.com

Annexure A**Brief profile of Mr. Rajiv Salvi**

Mr. Rajiv Salvi holds a degree in M.Sc in Organic Chemistry from Mumbai University and is a Certified Trichologist from International Association of Trichologists, Australia. He is also a recipient of two patents on natural anti lice preparation.

He has over 34 years of rich experience in the Industry including in areas of new product development, product improvement and packaging improvement. He joined OTC division of Piramal Enterprises Limited ('PEL') in September, 2009 as Associate Director R&D. Before joining PEL, he had worked with Zydus Cadila Healthcare Ltd. as Senior General Manager – F&D Consumer and OTC Products. He has also worked with companies like Marico Ltd. as Product Development Technologist, ICI India Ltd as Research Chemist and Garware Plastics & Polyester Ltd.

Piramal Phytocare Limited

[Formerly known as Piramal Life Sciences Limited] | CIN : L73100MH2001PLC132523

Registered Office: Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013, India

Secretarial Dept. : Tower Annexe 1st Floor Ganpatrao Kadam Marg Lower Parel Mumbai 400 013.

T +91 22 3046 7953 **F** +91 22 3046 7855

W www.piramalphytocare.com

Haribhakti & Co.


CHARTERED ACCOUNTANTS

18, Haribhakti Colony, Race Course Circle, Vadodara-390 007.
Tel.: (O) 91-265-234 0091, Tele Fax : 91-265-231 4495, E-mail: misa@haribhaktica.com

To,
The Board of Directors,
Piramal Phytocare Limited,
Mumbai.

1. We have reviewed the accompanying statement of Unaudited financial results of **Piramal Phytocare Limited** (Formerly known as Piramal Life Sciences Limited) ("the Company") for the period ended 31st December 2016 ("the Statement"), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Listing Regulations, 2015) with the stock exchanges. This statement is the responsibility of the Company's Management and has been approved by the Board of directors / committee of Board of Directors.
2. We have conducted our review in accordance with the Standards on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with accounting standards specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co.
Chartered Accountant
Firm, Reg No: 118013W


Hitesh J. Desai
Partner
M.No.: 037569



Date: 8th February, 2017
Place: Mumbai

PIRAMAL PHYTOCARE LIMITED

Piramal Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013.

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2016


Particulars	(Rs. in Lakhs)					
	Quarter Ended 31/12/2016	Quarter Ended 30/09/2016	Corresponding Quarter ended 31/12/2015	Year to Date Figures for Current Period Ended 31/12/2016	Year to Date Figures for Previous Period Ended 31/12/2015	Previous Year ended 31/03/2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income from operations						
Net Sales / Income from Operations (Net of excise duty)	141	116	225	322	553	632
Other Operating Income	-	-	-	-	-	-
Total Income from Operations (Net)	141	116	225	322	553	632
Expenses						
Cost of Materials Consumed	21	34	72	93	177	209
Purchase of Stock-in-Trade	7	3	14	17	17	15
Changes in inventories of finished goods, work-in-progress and stock-in-trade	16	14	(7)	4	16	12
Employee benefits expense	12	21	16	68	66	87
Depreciation and amortisation expense	1	1	115	3	347	463
Other Expenses (Net)	36	45	18	104	122	196
Total Expenses	93	118	228	289	745	982
Profit / (Loss) from operations before other income, finance costs and exceptional items	48	(2)	(3)	33	(192)	(350)
Other Income	5	7	4	19	15	26
Profit / (Loss) from ordinary activities before finance costs and exceptional items	53	5	1	52	(177)	(324)
Finance Costs	-	-	-	-	-	-
Profit / (Loss) from ordinary activities after finance costs but before exceptional items	53	5	1	52	(177)	(324)
Exceptional Items	-	-	-	-	-	-
Profit / (Loss) from ordinary activities before tax	53	5	1	52	(177)	(324)
Tax Expense (Including Deferred Tax)	-	-	-	-	-	-
Net Profit / (Loss) from ordinary activities after tax	53	5	1	52	(177)	(324)
Extraordinary Items (net of tax expense)	-	-	-	-	-	-
Net Profit / (Loss) for the period	53	5	1	52	(177)	(324)
Other Comprehensive (Income) / Loss	(1)	1	(0)	2	3	5
Total Comprehensive Income / (Loss)	54	4	1	50	(180)	(329)
Paid-up Equity Share Capital (Face Value Rs.10/- each)	2,596	2,596	2,596	2,596	2,596	2,596
Reserves (Excluding Revaluation Reserves)	-	-	-	-	-	(2,097)
Earnings Per Share (EPS)						
a) Basic and diluted EPS before extraordinary items for the period (Rs.)	0.2	0.0	0.0	0.2	(0.7)	(1.2)
b) Basic and diluted EPS after extraordinary items for the period (Rs.)	0.2	0.0	0.0	0.2	(0.7)	(1.2)



Notes:

1. The results for the quarter ended December 31, 2016 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 08, 2017.
2. The Company is engaged in the business of Phytopharmaceuticals which is the primary reportable business segment.
3. The Standalone Financial Results for the quarter and nine months ended December 31, 2016 have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2016, the Company has for the first time adopted Ind AS with a transition date of April 1, 2015.
4. The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

Description	(Rs. in Lakhs)	
	Quarter Ended 31/12/2015 (Unaudited)	Nine Months Ended 31/12/2015 (Unaudited)
Net profit/(Loss) as per Previous GAAP (Indian GAAP)	1	(180)
Actuarial Loss of gratuity actuarial valuation transferred to Other Comprehensive Income	(0)	3
Net profit as per Ind AS	1	(177)
Other Comprehensive Income	(0)	3
Total Comprehensive Income	1	(180)

For PIRAMAL PHYTOCARE LIMITED

Rajesh Laddha
 Director

 Mumbai
 February 08, 2017
